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 A prospective survey was conducted on 862 Enterobacteriaceae with reduced 
susceptibility to carbapenems. The Carba NP test, UV spectrophotometry and DNA 
microarray were used for detecting carbapenemase producers, and results compared to 
PCR and sequencing. The 172 carbapenemase producers were detected using the Carba 
NP test and UV spectrophotometry whereas DNA microarray failed to detect IMI 
producers. Use of the Carba NP test as first screening, followed by the use of molecular 
techniques has been defined as an efficient strategy for identification of carbapenemase-
producing Enterobacteriaceae. 
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 Carbapenemases lead to the ultimate evolution of resistance in Enterobacteriaceae, 
leaving virtually very few efficient antibiotics left (1, 2). The most clinically-significant 
carbapenemases in Enterobacteriaceae are: (i) Ambler class A enzymes including KPC, IMI 
and SME enzymes (1, 3, 4), (ii) metallo-β-lactamases (MBL) of VIM-, IMP- and NDM-types 
(5, 6), and (iii) OXA-48-like enzymes (7). Detection of carbapenemase producers include 
screening of patients at risk to be carriers of carbapenemase producers including patients 
who have been hospitalized abroad and implementation of efficient isolation procedures for 
carriers are the main features for limiting the spread of this emerging resistance trait (8-10). 
The biochemical Carba NP test, based on detection of carbapenem hydrolysis has been 
recently developed (11). Molecular methods such as simplex and multiplex PCRs, DNA 
hybridization and sequencing are also used for the identification of carbapenemase genes. 
 The aim of this study was to evaluate prospectively an efficient and cost-effective 
strategy for detection and characterization of carbapenemase-producing Enterobacteriaceae. 
From June 2011 to July 2012, 862 non-duplicate clinical Enterobacteriaceae isolates 
from worldwide origin were tested for characterization of the mechanisms leading to reduced 
susceptibility to carbapenems (Figure 1). The isolates were identified using  MALDI-TOF 
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mass spectrometry (Vitek MS, bioMérieux, La Balme-les-Grottes, France). Susceptibility 
testing was performed by determining MIC values using the Etest® (bioMérieux) on Mueller-
Hinton agar plates at 37°C and results were recorded according to US guidelines (CLSI), as 
updated in 2013 (12). All tested isolates were non susceptible to at least one of the three 
carbapenem molecules, imipenem, meropenem, or ertapenem. 
Detection of blaKPC, blaIMI, blaSME, blaGES, blaVIM, blaIMP, blaNDM, blaGIM, and blaOXA-
48 carbapenemase genes was performed by simplex PCR followed by sequencing (13). Results 
of PCR and sequencing were used as standards for the evaluation of the other detection 
techniques. A molecular detection of the β-lactamase genes was also performed for all 
carbapenemase producers (n=173) using a DNA hybridization array approach (Check-MDR 
CT103 array; Check-Points, Wageningen, The Netherlands) following the manufacturer 
instructions (16). 
Detection of carbapenemase production was performed by UV spectrophometry as 
previously described (14). It was also performed by using the Carba NP test (11). An 
improved version (faster and easier) of this test was performed with isolates grown on 
Mueller-Hinton agar plates (Becton Dickinson, Le Pont-de-Chaix, France) at 37°C for 18-22 
h, as previously described (see Supplementary data) (1, 15). 
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The statistical analyses were performed using χhi2 test. P values of <0.05 were 
considered as statistically significant. 
Among the 862 enterobacterial isolates tested, the PCR-based techniques followed by 
sequencing identified 172 carbapenemase producers. As compared to the PCR-based 
detection method, the UV spectrophotometry method and the Carba NP test were found to be 
100% sensitive and 100% specific for detecting carbapenemase producers (Table 1). Since the 
blaIMI gene was not included in the panel of carbapenemase genes detected by the Check-
MDR CT103, this array failed to identify the two Enterobacter spp. strains producing the 
IMI-1 carbapenemase, leading to a 98.8% sensitivity and 100% specificity (Table 1). The 
positive predictive values (PPV) were of 100 % for all the three techniques and negative 
predictive values (NPV) were of 100 % for UV spectrophotometry and Carba NP test, and of 
99.7 % for the Check-MDR CT103 array (Table 1). 
The DNA array was the only technique that could identify additional non-
carbapenemase β-lactamases. Indeed, 70% of the carbapenemase-producing 
Enterobacteriaceae additionally expressed at least one broad-spectrum β-lactamase, such as a 
plasmid-mediated cephalosporinase and/or an extended-spectrum ß-lactamase (Table 2).  
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Among the 172 carbapenemase producers, 65% were Klebsiella pneumoniae, 15% 
were Escherichia coli, 13% were Enterobacter spp., 5% were Citrobacter freundii, 1% were 
Serratia marcescens and 1% were Salmonella enterica (Table 2). The identified 
carbapenemases were of the OXA-48- (72%), KPC- (15%), NDM- (6%), VIM- (6%) and 
IMI-types (1%) (Table 2). The characterization of carbapenemase genes was done by 
sequencing as listed in Table 2. Regardless of the enterobacterial species considered, OXA-
48-like carbapenemases were predominant in our collection (Figure 1). KPC producers were 
mostly identified in K. pneumoniae compared to the other enterobacterial species (96%, 
p<0.001). On the opposite, NDM producers were equally distributed (p>0.05) among each 
type of enterobacterial species (Figure 1). 
Overall, this study showed 100% specificity and sensitivity for the Carba NP test and 
UV spectrophotometry to detect the production of a carbapenemase (Table 1) (11). 
Additionally, the PPV and NPV of both techniques were also 100 %. The Carba NP test was 
as efficient as the UV spectrophotometry method to detect carbapenemase producers but with 
significant advantages, since the Carba NP test is more rapid (<2h versus 24 h for UV 
spectrophotometry) and does not require any specific training. Its cost is less than 1 US$ per 
tested strain whereas UV spectrophotometric assay and PCR-based techniques require 
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additional equipment (UV spectrophotometer and sonicator for the UV spectrophotometric 
assay, consumables, reagents, and thermocycler for PCR assay). On the other hand, the 
Check-MDR CT103 failed to detect two IMI-1 producers, leading to 100% specificity, 98.8% 
sensitivity, 100% PPV and 99.7% NPV (Table 1 and Table 2). Since the Check-MDR CT103 
array is designed for its clinical use, it may detect the most clinically-relevant carbapenemase 
enzymes (KPC, VIM, IMP, OXA-48-like carbapenemase). In addition, it cannot discriminate 
between the different variants of a given carbapenemase. Additionally, this technique requires 
several successive steps (DNA extraction, ligation, PCR amplification, hybridization and 
detection) requiring 8 to 24 h. It also requires additional equipments (DNA extraction kit, 
thermocycler, thermomixer, Check-Points tube reader including the software) that cost ~ 
16,000 $ (16). Additionally, the use of this array on a daily routine basis may be limited by its 
cost (~ 100 US$) compared to the UV spectrophotometry (2-3 US$), Carba NP test (1 US$) 
and PCR-based testing (30 US$). However, the microarray technique may help to characterize 
the entire β-lactamase content of a single isolate by detecting also other broad-spectrum β-
lactamase genes. 
The diversity of carbapenemases identified here mirrors the worldwide dissemination 
of the four main described enzymes (KPC, VIM, NDM and OXA-48) (1). Additionally, our 
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results further highlight the wide dissemination of the OXA-48 carbapenemase in Europe 
(particularly in France) accounting for 72% of the whole carbapenemases (Figure 1) (7, 17), 
whereas KPC is the most widespread carbapenemase in the US. Of note, the KPC 
carbapenemases are nearly restricted to the K. pneumoniae species (25/26). On the opposite, 
OXA-48 and NDM were distributed among all enterobacterial species. 
Since the management of patients requires a rapid identification of carbapenemase 
producers (regardless of its type) (18), a diagnostic strategy for detection of carbapenemase 
producers in Enterobacteriaceae is proposed here (Figure 2). This strategy is based on: (i) the 
Carba NP test as the primary screening test for detection of a carbapenemase production, 
followed by (ii) a specific molecular characterization of the carbapenemase genes by simplex 
PCRs or DNA microarray. The initial step (susceptibility testing and Carba NP test) may be 
developed in any laboratory worldwide. Molecular identification of the carbapenemase genes 
may be also performed locally depending on the molecular techniques available, however it is 
not required for antibiotic stewardship or infection control purposes. 
In case of a negative result obtained with the Carba NP test, the mechanism 
responsible for carbapenem decreased susceptibility is not related to the production of a 
carbapenemase (e.g. reduced permeability of the outer membrane associated with over-
8
ht
tp
://
do
c.
re
ro
.c
h
expression of chromosomal or acquired AmpC and/or ESBL), therefore no additional test is 
required (17). In case of positive result with the Carba NP test, the use of a set of five simplex 
PCR (blaKPC, blaVIM, blaNDM, blaIMI and blaOXA-48-like) may then identify all carbapenemase 
genes of our collection (Figure 1, Table 2). However, this screening may be adapted to the 
local epidemiology as recently proposed for the detection of carbapenemase SME in the US 
(4). The DNA microarray may be more useful for epidemiological purposes or for infection 
control studies when high numbers of isolates have to be rapidly characterized (16). 
Additionally, this procedure may also detect potential new carbapenemases. Indeed, although 
molecular techniques are currently considered as “gold standard” for detection of 
carbapenemase producers, they are only able to detect known carbapenemase genes. With the 
proposed strategy, a positive Carba NP test followed by negative results using molecular 
thechniques may correspond to a novel carbapenemase that may be further characterize using 
cloning experiments (Figure 2). 
 This is the first prospective study evaluating at an international level the value of the 
different techniques for detecting carbapenemases. The strategy proposed for detection of 
carbapenemase producers presents several advantages for treating infected patients and for 
isolation of carriers. Indeed, it will lead to a rapid identification of carbapenemase producers 
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(< 2 h) using the Carba NP test, allowing a better antibiotic stewardship (18). This strategy 
may also have a significant impact for preventing the development of nosocomial outbreaks 
by acting rapidly on the management of carriers (isolation, cohorting) as demonstrated for 
KPC outbreaks at least in Israel (19). Finally, since the first step of this strategy which 
includes susceptibility testing and the Carba NP test is based on cheap techniques, it may be 
followed worldwide, and therefore contribute to limit the spread of what has been recently 
termed the new Red Plague (20). 
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FIGURES LEGENDS 
Figure 1. Distribution of the different carbapenemase types among carbapenemase-producing 
Enterobacteriaceae. 
 
Figure 2. Chart flow for detection and characterization of carbapenemase producers among 
Enterobacteriaceae. The Carba NP test is used for a rapid differentiation between 
carbapenemase and non-carbapenemase producers. The second step includes molecular 
techniques (PCRs or DNA microarray) for precise identification of carbapenemase genes. 
Bold arrows indicate the preferred way for identification of carbapenemase genes. This 
second step may be followed only in University hospitals or large-size microbiology 
laboratories. 
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Table 1. Main characteristics of Carba NP test, UV spectrophotometry method and DNA microarray for the detection of carbapenemase-producing Enterobacteriaceae 
 
Characteristics of the tests 
Detection of carbapenemase-producing Enterobacteriaceae 
PCR + sequencing  Carba NP test UV spectrophotometry DNA microarray 
Test efficiency     
 Sensitivity 100% 100% 100%      98.8% 
 Specificity 100% 100% 100% 100% 
 PPV 100% 100% 100% 100% 
 NPV 100% 100% 100%      99.7% 
Other characteristics     
 Rapidity 24-48h < 2h 12-24h 8-24h 
 Cost $$ $ $ $$$ 
 Expertise needs ++ + +++ ++ 
 Complete gene identification + - - +/- 
PPV, Positive predictive value 
NPV, Negative predictive value 
The number of $ correlates with the effective price of the test 
The number of + correlates with the expertise and training needed to perform and interpret the test 
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Table 2. Molecular characterization of carbapenemase-producing Enterobacteriaceae using sequencing and DNA microarray 
Carbapenemase 
type 
Carbapenemase 
variant Species n 
DNA microarray 
Acquired penicillinase ESBLs Acquiredcephalosporinase Carbapenemase 
KPC KPC-2 K. pneumoniae 7 TEM-type None None KPC 
 2 TEM-type CTX-M type 1 None KPC 
 1 TEM-type CTX-M type 9 None KPC 
 10 TEM-type SHV-type None KPC 
C. freundii 1 TEM-type None None KPC 
 KPC-3 K. pneumoniae 4 TEM-type None None KPC 
 1 TEM-type CTX-M type 1 None KPC 
VIM VIM-1 K. pneumoniae 2 TEM-type SHV-type None VIM 
E. cloacae 1 TEM-type None None VIM 
   1 TEM-type SHV-type None VIM 
   C. freundii 1 TEM-type None None VIM 
 VIM-2 C. freundii 4 TEM-type TEM-type None VIM 
 VIM-4 K. pneumoniae 1 TEM-type None None VIM 
NDM NDM-1 E. coli 1 None CTX-M type 1 None NDM 
   1 TEM-type CTX-M type 1 None NDM 
1 TEM-type + SHV-type CTX-M type 1 None NDM 
K. pneumoniae 1 None None CMY-2-like NDM 
   1 None CTX-M type 1 None NDM 
   1 TEM-type CTX-M type 1 None NDM 
E. cloacae 1 TEM-type CTX-M type 1 None NDM 
1 TEM-type CTX-M type 1 + SHV-type None NDM
Salmonella spp. 1 TEM-type None DHA-type NDM 
IMI IMI-1 E. cloacae 1 TEM-type None None None 
E. asburiae 1 None None None None 
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OXA-48-like OXA-48 E. coli 4 None None None OXA-48 
   7 TEM-type None None OXA-48 
   1 TEM-type None CMY-2-like OXA-48 
   1 None CTX-M type 1 None OXA-48 
   7 TEM-type CTX-M type 1 None OXA-48 
   1 TEM-type + SHV-type CTX-M type 1 None OXA-48 
   1 TEM-type CTX-M type 9 None OXA-48 
K. pneumoniae 5 None None None OXA-48 
   1 TEM-type None None OXA-48 
   1 None None DHA-type OXA-48 
   5 None CTX-M type 1 None OXA-48 
   64 TEM-type CTX-M type 1 None OXA-48 
   1 TEM-type CTX-M type 1 CMY-2-like OXA-48 
   1 None CTX-M type 9 None OXA-48 
E. cloacae 1 None None None OXA-48 
   1 None CTX-M type 1 None OXA-48 
   10 TEM-type CTX-M type 1 None OXA-48 
4 TEM-type + SHV-type CTX-M type 1 None OXA-48 
E. hormacchei 1 TEM-type CTX-M type 1 None OXA-48 
C. freundii 1 TEM-type SHV-type None OXA-48 
C. freundii 1 SHV-type CTX-M type 1 None OXA-48 
S. marscescens 1 None None None OXA-48 
   1 TEM-type CTX-M type 1 None OXA-48 
 OXA-162 C. freundii 1 None SHV-type None OXA-48 
 OXA-181 E. coli 1 None CTX-M type 1 None OXA-48 
K. pneumoniae 2 TEM-type CTX-M type 1 None OXA-48 
NDM + OXA-48-
like NDM-1 + OXA-181 K. pneumoniae 1 TEM-type CTX-M type 1 None NDM + OXA-48 
18
ht
tp
://
do
c.
re
ro
.c
h
19
ht
tp
://
do
c.
re
ro
.c
h
MIC determination: detection of
reduced susceptibility to carbapenems
Carba NP test
- +
< 2 h
Therapy adaptation
Non-carbapenemase 
producer
Carbapenemase 
producer
 
Implementation of 
hygiene measures
Simplex PCR for 
blaKPC, blaVIM, blaNDM,
blaOXA-48-like genes
DNA microarray
3-5 h 8-24 h
Simplex PCR for other 
carbapenemases genes
+ +-
 
blaIMI, blaSME,  blaSFC-1, 
blaIMP, blaGIM, blaAIM, 
blaKHM
24-48h 24-48h
3-5 h
24-48h
+ -
New carbapenemase
Sequencing
Cloning experiments
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